Rethinking clinical trials for cytostatic drugs.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12835674.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The failure of many cytostatic agents in Phase III clinical trials for treatment of common cancers has led researchers to question current approaches to trial development. Recent studies offer some clues as to what is wrong with two particular aspects of clinical trial design--survival as an end point and simultaneous combination with cytotoxic chemotherapy--and indicate possible alternatives.
Medical subject headings
- Antineoplastic Agents
- Clinical Trials as Topic